Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.

Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD.

Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient ...

Insulet Corporation PODD announced favorable RADIANT trial clinical data for its Omnipod 5 at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”).

Below is Validea's guru fundamental report for INSULET CORP (PODD). Of the 22 guru strategies we follow, PODD rates highest using our Twin Momentum Investor model based on the published strategy ...

Insulet (PODD) announced its revolutionary Omnipod 5 Automated Insulin Delivery System is now available in Australia and will soon be offered ...

Insulet Corp. closed 8.17% short of its 52-week high of $289.46, which the company reached on February 7th.

The company also announced its intention to amend its existing credit agreement to, extend the maturity of the company’s revolving credit facility from 2028 to 2030 and increase the amount of ...